Ann Rheum Dis: The effect of psiphon VS low-dose autumn daffodils in primary care facilities to treat gout recurrence

The purpose of this study was to compare the effectiveness and safety of gout recurrence in primary care for the treatment of pyrethrosinandandandandandandandande and low-dose autumn daffodilsthis is a multicenter open-label randomized trial that recruited adults with gout attacks from 100 general practitioners, randomly assigned epsometry and low-dose equinox to treat gout attacksAdults recruited from 100 General Practitioners for gout attacks were randomly assigned to 750 mg of epson, then 250 mg every 8 hours for 7 days, or 500 mcg for low doses of autumn daffodils, 3 times a day, for 4 daysThe main result was a change in the intensity of the most severe pain (0-10 digital scoring table) and baseline for the last 24 hours measured daily for the first 7 days: the average change between the groups and baselines by treatment intent over a period of 1-7 daysresults, between 29 January 2014 and 31 December 2015, we recruited 399 participants (Pson n?200, Autumn Daffodiln n?199), of which 349 (87.5%) completed the main results data on day 7Average pain change scores for 1-7 days did not differ significantly between groups (autumn daffodils and xenon: average difference -0.18; 95% CI-0.53 to 0.17; p-0.32)In 1-7 days, the autumn daffodil group was more common than the fengo group (45.9% vs 20.0%; OR 3.31; 2.01 to 5.44) and headache (20.5% vs 10.7%; 1.92; 1.03 to 3.55), but less common (4.8% vs 19.3%; 0.24.14.51)in general, the results showed that gout authors were randomly taken with either fenclath or low doses of ethnoda, with no difference in pain intensity within 7 daysIn the absence of contraindications, the presence of fenclath-serapin causes fewer side effects and supports the first-line treatment of gout attacks in primary care